//fpnotebook.com/
Lo/Ovral
Aka: Lo/Ovral, Lo-Ovral, LoOvral, Cryselle, Low-Ogestrel
- See Also
- Oral Contraceptive
- Oral Contraceptive Drug Interaction
- Oral Contraceptive Selection
- Oral Contraceptive Side Effect Management
- Oral Contraceptive-Related Uterine Bleeding Management
- Preparations (Norgestrel 300 mcg / Ethinyl Estradiol 30 mcg)
- Lo-Ovral
- Cryselle
- Low-Ogestrel
- Components
- Norgestrel 300 mcg (see preparation above)
- Ethinyl Estradiol 30 ug
- Effects
- Relative Progestational Activity: 0.8 (moderate)
- Estrogenic Activity: 25 (moderate)
- Androgenic Activity: 0.46 (high)
- Adverse Effects: Pill associated problems
- Indications to switch to Ortho Novum 777
- Acne Vulgaris (lower androgen)
- Indications to switch to Ortho Cyclen
- Increased Appetite (lower Progestin)
- Major Depression provoked (lower Progestin)
- Indications to switch to Loestrin 1.5/30
- Breast Tenderness or engorgement (lower Estrogen)
- Headaches (lower Estrogen)
- Moodiness (less Estrogen or more Progestin)
- Weight gain (less Estrogen or more Progestin)
- Libido decreased (more androgen)
- Indications to switch to Ortho Novum 1/35
- Break-through bleed days 1-9 (more Estrogen)
- Break-through bleed all of month (more Estrogen)
- Menses too light (more Estrogen, less Progestin)
- Indications to switch to Demulen 1/35
- Break-through bleed days 10-21 (more Progestin)
- Heavy Menses (more Progestin or less Estrogen)
- Dysmenorrhea or Menstrual Cramps (more Progestin)
- References
- Cerel-Suhl (1999) Am Fam Physician 60(7):2073 [PubMed]
- Speroff (1993) Obstet Gynecol 81:1034-47 [PubMed]
- Dickey (1998) Managing Contraceptive Pill Patients